Research Topics
| Charles DeBattistaSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depressionCharles DeBattista
Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford, CA 94305, USA
J Psychiatr Res 45:64-75. 2011..To evaluate the efficacy of rEEG(®)-guided pharmacotherapy for the treatment of depression in those circumstances where rEEG and STAR*D provided different recommendations...
A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunctionCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif 94305, USA
J Clin Psychiatry 66:844-8. 2005..In this double-blind trial, the efficacy of a standard dose of bupropion sustained release (SR) is evaluated in the treatment of SSRI-induced sexual dysfunction...- Executive dysfunction in major depressive disorderCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
Expert Rev Neurother 5:79-83. 2005..While few studies have examined the treatment of executive dysfunction in depression, preliminary work suggests that both pharmacologic interventions and psychosocial interventions such as problem solving therapy may be efficacious... - The use of mifepristone in the treatment of neuropsychiatric disordersCharles DeBattista
Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
Trends Endocrinol Metab 17:117-21. 2006..Preliminary studies suggest that mifepristone might have a role in the treatment of a number of neuropsychiatric disorders... - Augmentation and combination strategies for depressionCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA 94305, USA
J Psychopharmacol 20:11-8. 2006..This paper summarizes the state of the evidence for commonly used augmenting strategies and explores preliminary findings for more investigational approaches... - A prospective trial of modafinil as an adjunctive treatment of major depressionCharles DeBattista
Stanford University School of Medicine, Depression Research Clinic, Stanford, CA 94305 5723, USA
J Clin Psychopharmacol 24:87-90. 2004..Modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression... - Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depressionCharles DeBattista
Corcept Therapeutics, Menlo Park, California, USA
Biol Psychiatry 60:1343-9. 2006..Recent studies have suggested that the antiglucocorticoid, mifepristone might have a role in the treatment of PMD. The current study tested the efficacy of mifepristone treatment of the psychotic symptoms of PMD... - Utility of atypical antipsychotics in the treatment of resistant unipolar depressionCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, California 94305, USA
CNS Drugs 23:369-77. 2009..This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant unipolar depression is reviewed... - A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressantsCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine Stanford, CA 94305 5723, USA
J Clin Psychopharmacol 23:27-30. 2003..This prospective, open-label trial supports the use of bupropion SR in the augmentation of SSRIs and venlafaxine. Placebo controlled trials should be completed to further evaluate the efficacy of this strategy... - Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effectsCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
Curr Drug Saf 5:263-6. 2010..In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics... - Update on augmentation of antidepressant response in resistant depressionCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
Curr Psychiatry Rep 7:435-40. 2005..We review the status of augmentation strategies in the treatment of depression... - The neuropsychological profile of psychotic major depression and its relation to cortisolRowena G Gomez
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
Biol Psychiatry 60:472-8. 2006..We predicted that higher cortisol levels would be associated with greater cognitive deficits... - Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled studyCharles DeBattista
Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, 401 Quarry Road, Room 2137, Stanford, CA 94305, USA
J Clin Psychiatry 64:1057-64. 2003..In this study, we examined the utility of modafinil as an adjunct therapy to treat fatigue and sleepiness in patients with major depression who are partial responders to antidepressants... - A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interactionChristine M Blasey
Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
Contemp Clin Trials 30:284-8. 2009.... - The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in ratsKatherine L Beebe
Corcept Therapeutics, Menlo Park, CA 94205, USA
Behav Brain Res 171:225-9. 2006..0002). Results suggest that mifepristone, a potent glucocorticoid antagonist, may both reduce and prevent olanzapine-induced weight gain in rats... - C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's diseaseCharles DeBattista
Corcept Therapeutics, 275 Middlefield Road, Menlo Park, California 94025, USA
Curr Alzheimer Res 2:125-9. 2005..The purpose of this study is to determine the effects of glucocorticoid receptor blockade with mifepristone on cognition in Alzheimer's disease... - Slowing the progression of cognitive decline in Alzheimer's disease using mifepristoneJoseph K Belanoff
Corcept Therapeutics, Inc, Menlo Park, CA 94025, USA
J Mol Neurosci 19:201-6. 2002..Additionally, this study test the hypothesis that AD subjects with elevated cortisol at baseline will perform more poorly on neuropsychological exams that do subjects with low cortisol... - An open label trial of C-1073 (mifepristone) for psychotic major depressionJoseph K Belanoff
Corcept Therapeutics Inc, Menlo Park, California 94025, USA
Biol Psychiatry 52:386-92. 2002..CONCLUSIONS: These results suggest that short term use of GR antagonists may be effective in the treatment of psychotic major depression and that further blinded studies are warranted... - The efficacy of divalproex sodium in the treatment of agitation associated with major depressionCharles DeBattista
Depression Research Clinic, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305-5723, USA
J Clin Psychopharmacol 25:476-9. 2005..Controlled clinical trials are needed to fully evaluate the utility and symptom specificity of divalproex sodium in depression... - Safety of antidepressants in the elderlyBarbara R Sommer
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
Expert Opin Drug Saf 2:367-83. 2003..Drug interactions, side effects and particular challenges to the older patient will be described. The authors will then advise a general strategy for prescribing antidepressants... - Effects of major depression diagnosis and cortisol levels on indices of neurocognitive functionRowena G Gomez
Pacific Graduate School of Psychology, 405 Broadway, Redwood City, CA 94063, USA
Psychoneuroendocrinology 34:1012-8. 2009..Our study suggests that cortisol has an independent effect on verbal memory. Also, our study produced evidence of an interaction between diagnosis and cortisol on response inhibition... - Detecting psychotic major depression using psychiatric rating scalesJennifer Keller
Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305 5723, USA
J Psychiatr Res 40:22-9. 2006..The aim of this study was to assess whether individual or clusters of psychiatric symptoms can differentiate patients with psychotic major depression (PMD) from those with nonpsychotic depression (NPMD)... 
Depression and smoking cessation: does the evidence support psychiatric practice?Anna Lembke
Department of Psychiatry, Stanford University, Stanford, CA, USA
Neuropsychiatr Dis Treat 3:487-93. 2007..More research is needed to understand the relationship between depression and quitting smoking, but current clinical evidence suggests more resiliency among depressed smokers than common clinical wisdom would dictate...- Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trialH George Nurnberg
Department of Psychiatry, University of New Mexico School of Medicine, 2400 Tucker NE, MC 09 5030, Albuquerque, NM 87131 0001, USA
JAMA 300:395-404. 2008..Antidepressant-associated sexual dysfunction is a common adverse effect that frequently results in premature medication treatment discontinuation and for which no treatment has demonstrated efficacy in women... - A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepinessMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 66:85-93. 2005.... - Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension studyMichael E Thase
Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
CNS Spectr 11:93-102. 2006..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms... - Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepinessMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, and Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
Ann Clin Psychiatry 19:153-9. 2007..This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue... - HPA axis activation in major depression and response to fluoxetine: a pilot studyElizabeth A Young
Department of Psychiatry, The Mental Health Research Institute, University of Michigan, 205 Zina Pitcher Place, Ann Arbor, MI 48109 0729, USA
Psychoneuroendocrinology 29:1198-204. 2004..This may reflect the greater severity of subjects with HPA axis dysregulation or the need to normalize the HPA axis with medications for optimal response...